The dominant Chlamydia trachomatis antigen in experimentally infected animals and naturally infected humans, and the antigen recognized by serotyping monoclonal antibodies (MAbs), is the major outer membrane protein of 40 kDa (MOMP). MOMP is thought to provide rigidity to the chlamydial cell wall by extensive disulfide bond crosslinking (7, 10) and to function as a porin (2) ; it may also be an adhesin (17) . Because anti-MOMP antibodies react with whole organisms (15) and because MOMP is found in outer membrane preparations (3), portions of this molecule are probably surface exposed. Detailed knowledge of the structure of MOMP and its diversity among C trachomatis strains is of considerable importance, as this molecule is currently a leading candidate for development as a vaccine.
The DNA sequences of MOMP genes from several serovars have been determined, and comparison of these sequences has led to models for MOMP structure (14) and organization (1) . According to these models, the gene is divided into five conserved domains and four variable domains (VDI through VDIV). Cysteine residues, which may be involved in disulfide bonds, are strictly conserved and fall into the conserved domains. These conserved domains of the protein are thought to be buried in the cell membrane and thus not accessible to antibodies. In contrast, most of the amino acid differences between serovars occur in the VDs, which are probably surface exposed because they are accessible to antibodies. The sequences of the MOMP VDs for all 15 serovars have been determined (23) , and comparison of these sequences confirms the heterogeneity in the VDs from serovar to serovar.
In typing studies involving large numbers of clinical isolates carried out in our laboratory (18) patterns with a panel of MAbs. We report here the MOMP VD sequences for these and the L2a C. trachomatis serovariant and compare them with the VD sequences for prototypic D, I, and L2 serovar strains. Comparison of the altered MAb reactions and MOMP VD sequences of the variants identifies which portions of MOMP these MAbs recognize, information which will be useful in analyzing which MOMP epitopes are important in antibody recognition.
MATERIALS AND METHODS
Bacterial strains. The C. trachomatis strains examined in this study were D (UW3, MT13), Da (TW448, MT199), D-(NL326, TB39, MT157, RB205), D* (MTS2, ICD033), I (UW12, MT155), Ia (NL1540, MT165), I-(MT518, MT741, MT1196), L2 (434), and L2a (UW396). We obtained several strains (UW3, TW448, UW12, 434, UW396) from Cho-Chou Kuo (Department of Pathobiology, University of Washington); these strains were typed by San-Pin Wang (Department of Pathobiology, University of Washington) by a microimmunofluorescence method (20) .
The serovariants reported here (Da, D-, D*, Ia, I-, L2a) were isolated in our laboratory (with the exception of Da/TW448 and L2a/UW396) and identified as variants by a microtiter plate typing method (18) . A D* variant (MTS2) was originally designated Ea by Suchland and Stamm (18) , but its name was changed after its MOMP gene VD sequence was determined. The methods used for isolation and growth of C trachomatis were as previously described (13 (6) . Labeled oligonucleotides were annealed directly to purified RNA as described by Yuan et al. (23) each of the four (A, C, G, and T) tubes. The tubes were incubated at 50°C for 45 min; then 2 ,u of stop solution containing 100% formamide, 0.3% xylene cyanol FF, and 0.3% bromphenol blue was added. The sequencing reactions were then heated at 90°C for 4 min, and 4-,ul samples were loaded on 6% acrylamide-7 M urea sequencing gels.
(ii) Direct sequencing of polymerase chain reaction-amplified MOMP DNA from I, Ia, I-, L2, and L2a isolates. Samples (10 ,ul) 5-pA sample of each amplification reaction was analyzed by agarose gel electrophoresis for specificity and yield. The remaining reaction product was purified from nonspecific reaction products and amplification primers in low-meltingtemperature agarose gels and then sequenced directly by the method of Thien (19) .
(iii) D* MOMP cloning and sequencing in M13. Chromosomal DNA from the two D* serovariants was isolated from organisms purified by 30% Renografin differential centrifugation and digested with the restriction endonucleases XbaI and SphI. Total digests were separated by electrophoresis in 0.6% low-melting-temperature agarose gels; the fragments from 900 to 1,100 bp were excised from the gel, extracted, and precipitated. Purified 1.0-kb fragments were ligated to pUC19, and the DNA from approximately 5,000 transformants was hybridized to radiolabeled oligonucleotide oDV-DIII. Plasmid DNA was extracted from hybridizing colonies and digested with XbaI and SphI, and the digests were separated by electrophoresis in a 0.6% agarose gel. Recombinant plasmids with a 1.0-kb XbaI-SphI insert were digested with the restriction endonuclease SspI, since the MOMP gene contains an internal SspI site (14) . The 1.0-kb XbaISphI fragments with this internal SspI site were further subcloned into replicative form M13; single-stranded recombinant M13 DNA was extracted, and its nucleotide sequence was determined by the method of Sanger et al. (12) with primers oDVDI, oBVDII, and oDVDIII and the M13 universal primer.
Primers. Synthetic oligonucleotide primers derived from the MOMP DNA sequences (14, 23) 
RESULTS
MAb reactions. The first C. trachomatis serovariants (Da, Ia, L2a) were discovered because they reacted similarly to their prototype serovars (D, I, L2) with most MAbs but differed from these prototypes in reactions with a subset of MAbs (21, 22) . In typing studies carried out in our laboratory, we identified three additional serovariants (D-, D*, I-) that also had MAb reactions close to those of their prototype serovars (D and I) but also possessed minor MAb reaction differences ( Figure 1 summarizes the amino acid sequence differences found for the D group. In VDI, one of the two Da variants examined, strain TW448, had a sequence difference from the prototype that resulted in a valine substitution at amino acid 74. The seqaences of the second Da strain and all four D-strains were identical to that of the D prototype strain in VDI. Three of the four D-strains had a sequence change that resulted in a serine substitution at amino acid 140 in VDII. The nucleotide sequences of VDIV of the two Da variants that we examined both varied at amino acid 312, resulting in a threonine substitution. All four D-serovariants had a sequence variation, also in VDIV, that also resulted in a threonine substitution but at amino acid 305. The two D* variants differed at position 310, with an alanine substituted for threonine.
(ii) I group sequences. The I group sequence variations are summarized in Fig. 2 . Both Ia variants had an isoleucine substitution at amino acid 71 in VDI. The three I-variants also had a change at this position but substituted a threonine. Only one of the two Ia but all of the I-variants differed from the prototype at amino acid 152 in VDII, resulting in an isoleucine substitution. All of the Ia and I-variants had a change in VDIII which resulted in a threonine for isoleucine substitution. The sequence variation among the I, la, and Iorganisms in VDIV is considerable. All of the Ia and 1-variants had the sequence A-GSD-D at amino acids 310 through 316 compared with the sequence S-A-E-E for the I serovar. This included a serine insertion at amino acid 313 that is not present in the I sequence.
(iii) L2 group sequences. The L2 and L2a sequence summary is shown in Fig. 3 . The L2a variant had only one sequence difference from the L2 prototype, resulting in a threonine substitution at amino acid 144 in VDII.
DISCUSSION
During the course of a large typing study in our laboratory (18) , three new C. trachomatis serovariants (D-, D*, I-) were identified. These variants were detected by MAb reaction patterns that differed from those of their prototype strains. To confirm the MAb reactions of these serovariant strains and to determine their molecular basis, we sequenced the DNA encoding the MOMP VDs from the prototype strains and for several isolates of each variant as well as that from the previously identified variants Da, Ia, and L2a. Each variant differed from its respective prototype by at least one amino acid in the MOMP VD.
The sequences of the VDs which we determined for all the prototypes and for the Da, Ia, and L2a variants agreed in general with those determined by others (5, 23) with several exceptions. We did not find the T-for-C change reported by Dean et al. (5) in codon 292 in VDIV from any of the Da, D-, and D* variants that we examined. In addition, Dean et al. (5) found an isoleucine substitution at amino acid 152 in VDII from Ia variant UW-202. We found this same substitution but in only one of the two Ia variants (MT165) that we examined. We also found a valine substitution at amino acid 74 in VDI in the same variant (TW448) examined by Dean et al. (5), but their sequence did not include this change. It thus appears that our TW448 strains, which have been passed in separate laboratories, have divergent MOMP sequences.
Recently, Poole and Lamont (11) determined the sequences of the fourth VDs from 125 C. trachomatis isolates in clinical specimens. By comparing these sequences with those of prototype serovars, they typed all isolates and also found sequence variants, including one D-variant with the same MOMP VD nucleotide sequence reported here. They did not serotype these strains.
An analysis of the different MAb reactions and MOMP VD sequence changes in the variants provides additional information about where subspecies-or serovar-specific determinants are located in the MOMP VDs. We infer that the common changes found in VDIV (Fig. 1) are probably responsible for the altered MAb reactivities between the D prototype and its variants because they are the changes that all the variants had in common. The threonine substitutions at amino acid 305 in the D-variant VDIVs probably resulted in the loss of reactivity of these strains with the subgroupspecific MAbs BB-11 and LV-23. The threonine at position 312 in the Da variants is probably required, however, by the serovariant specific MAb DP-1 because this antibody reacted only with the Da variants and not with D or Dorganisms. The threonine at position 310 is probably bound by MAb JG-9, since D* variants with an alanine substitution here are no longer recognized by this subspecies MAb. This alanine must also allow better recognition by the subspeciesspecific MAb LV-23, since it binds D* variants with stronger affinity.
VDIV has been shown to possess subspecies-specific determinants (1) . Since the subspecies-specific MAbs BB-11 and LV-23 reacted differently with D and D-strains and their sequences only differed significantly in VDIV, our results confirm the location of subspecies-specific determinants in this domain. VDIV may also possess or be involved in D serovariant reactivities because the serovariant-specific MAb DP-1 reacted only with Da variants. Using proteolytic fragments and subclones of MOMP, Newhall et al. (9) showed that the D serovar possesses serovar-specific determinants in VDIV.
Serovar I subspecies-specific determinants may reside in VDIII or VDIV, since the Ia and I-variants all contained changes in both VDs (Fig. 2 ) and none reacted with the subspecies-specific MAb AC-11. The I serovar may also contain subspecies specificities in VDI, since it is in this domain that the Ia and I-variants had separate differences from the I prototype and reacted differently with the subspecies-specific MAb PE-5.
The L2 serovar probably has serovar-specific determinants in VDII, since this is the region where the L2a variant differed in its sequence (Fig. 3) , resulting in a different reactivity with the serovar-specific MAb LV-27. Others have also reported that L2 has serovar-specific determinants in VDII (1, 16 
TTG GCT GMA GCA ATC TTG GAT GTC ACT ACT CTA MAC CCG ACC ATC GCT GGT MAA GGA ACT GTG GTC TCT TCC GCA GMA MAC GMA CTG GCT la (N11540) (Fig. 2) . These changes result in Ta and P-VDIV sequences identical to the serovar H VDIV sequence (Fig. 2) possible that a recombination event between the MOMP genes of an I and an H serovar occurred to generate the composite MOMP of Ia and I-variants. It is also possible that individual point mutations accumulated in the VDIV of the variants, finally resulting in a VDIV resembling that of an H serovar. If so, this mechanism (accumulating point mutations) does not explain how three nucleotides were simultaneously added to encode the additional alanine found.
The MAb GG-11 confirms that the Ia and I-variants have MOMP VD amino acid sequences with immunogenicities similar to that of the H serovar and different from that of the I serovar ( Table 2 ). The MAb GG-11 reacted lightly with Ia, I-, and H strains but not with I organisms. Thus GG-11 probably reacts with the amino acids in VDIV of Ia, I-, and H organisms but does not react with the different sequence in VDIV of the I serovar.
Others have reported clinical strains that have MOMP sequence changes, but these variants were unchanged in their antibody reactivity or were not available for antibody typing (8, 11) . The variants described here were originally identified because they react differently with typing MAbs. Certain subspecies-and serovar-specific MAbs are able to neutralize C. trachomatis infectivity (24) . It will be interesting to determine whether the serovariants described in these studies are also neutralized by the MAbs that block infectivity of the prototype strains. Corresponding serovariant neutralization alterations would imply a biological consequence of MOMP sequence changes.
